Austrian biotech company Calyxha Biotechnologies GmbH announced the grant of European Patent No. EP3383381.
The Austrian biotech incubator and accelerator CEBINA GmbH announces the initiation of several collaborative projects that address the global health…
We thank Michael Krebs, the long-term member of the VBCF supervisory board, for his engagement in VBCF’s development and his invaluable contribution…
The VBCF is a proud member of the VCDI - Vienna COVID-19 Diagnostic Initiative
The COVID-19 pandemic poses an enormous threat for healthcare systems and economies in Austria, Europe and the world. In this time of crisis,…
SARS-CoV-2, the virus causing coronavirus disease-19 (COVID-19), is spreading worldwide at a fast pace. In a concerted effort including researchers…
On March, 21st, 2020, Alwin Köhler was announced as the new Director of the Max Perutz Labs Vienna. He holds a joint Professorship for Molecular…
In a new study published in the Journal Science Advances, the Bell lab at IMBA reveals how multiple highly-conserved chromatin modifying complexes…
Valneva has successfully completed an End-of-Phase 2 meeting with the U.S. Food and Drug Administration (FDA) and agreed on the clinical development…
Valneva today provided an update on its operations as the COVID-19 situation evolves.
Read more
A marvel of complexity, the nucleus is the command center of the cell – harboring information, codes and controlled access. But different from…
Valneva announced that the Food and Drug Administration (FDA) has approved the extension of the shelf life of its Japanese encephalitis vaccine IXIARO…
